The S protein is the target of neutralizing antibodies generated by infection (Jiang et al., 2020) or vaccination (Folegatti et al., 2020; Jackson et al., 2020; Keech et al., 2020) as well as monoclonal antibody (mAb) drugs currently in clinical trials and/or approved for Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) (Chen et al., 2021; Hansen et al., 2020; Jones et al., 2020; Pinto et al., 2020). The gene discussed is PROS1; the disease is infection.